Pidilizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | PD-1 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6424H9920N1704O2002S48 |
| Molar mass | 147.43 kg/mol g·mol−1 |
Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases.[1][2] Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, but this is currently uncertain.[3] Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.
Clinical trials
It had encouraging results by 2011 from phase II clinical trials for diffuse large B-cell lymphoma.[4] A phase II open-label study in combination for relapsed follicular lymphoma found good results compared to usual response rates. An add-on trial for multiple myeloma is ongoing.[5]
References
- ^ Westin; et al. (2014). "Safety and Activity of PD1 Blockade by Pidilizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: a Single Group, Open-label, Phase 2 Trial". Lancet Oncol. 15: 69–77. doi:10.1016/S1470-2045(13)70551-5. PMC 3922714. PMID 24332512.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pidilizumab, American Medical Association- needs login.
- ^ http://www.fiercebiotech.com/story/anti-pd-1-well-no-says-medivation-partial-hold-forces-halt-pivotal-cancer-s/2016-01-26
- ^ Teva Invests $19M More in CureTech After Positive Phase II DLBCL Data. Sept 2011
- ^ "Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2015-08-22.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |